title: [Chryseobacterium spp., a new opportunistic pathogen associated with cystic fibrosis?].
abstract: BACKGROUND
  There is an increase in the isolation of non-fermenting gramnegative bacilli in patients with cystic fibrosis (CF). The present study evaluates the frequency of isolates of Chryseobacterium spp., analyzing its characteristics, resistance patterns and clinical outcome of patients.
  
  
  METHODS
  It has been collected all respiratory isolates of Chryseobacterium spp. of patients attended in the CF unit of Hospital de la Princesa for three years (march 2009-march 2012). For phenotypic and genotypic identification and sensitivity study conventional methodology was used. For the assessment of the patients lung function was considered the forced expiratory volume in one second (FEV1) and the results were analyzed with SPSS.
  
  
  RESULTS
  There was an increase in the incidence of Chryseobacterium spp. with 17 isolates from 9 patients. Three patients had chronic colonization by this microorganism and one showed significant impairment of lung function. Seven patients showed also colonization with Staphylococcus aureus and 4 of them with Pseudomonas aeruginosa.
  
  
  CONCLUSIONS
  Chryseobacterium spp. should be considered as a new emerging opportunistic pathogen in patients with CF. It is essential the clinical and microbiological monitoring of this group of patients for detection of Chryseobacterium spp. colonization and to prevent the chronic infection. In these circumstances it must assess its possible eradication, though its clinical impact is unknown. Cotrimoxazole being the best treatment option.
authors.affiliation: Servicio de Microbiología, Hospital Universitario de la Princesa, Madrid, España; Instituto de Investigación del Hospital de la Princesa, Madrid, España. Electronic address: alba_guiu@hotmail.com.
authors.forename: Alba
authors.initials: A
authors.lastname: Guiu
authors.affiliation: Servicio de Microbiología, Hospital Universitario de la Princesa, Madrid, España; Instituto de Investigación del Hospital de la Princesa, Madrid, España.
authors.forename: Buenaventura
authors.initials: B
authors.lastname: Buendía
authors.affiliation: Servicio de Microbiología, Hospital Universitario de la Princesa, Madrid, España; Instituto de Investigación del Hospital de la Princesa, Madrid, España.
authors.forename: Laura
authors.initials: L
authors.lastname: Llorca
authors.affiliation: Unidad de Fibrosis Quística, Servicio de Neumología, Hospital Universitario de la Princesa, Madrid, España; Instituto de Investigación del Hospital de la Princesa, Madrid, España.
authors.forename: Rosa María
authors.initials: RM
authors.lastname: Gómez Punter
authors.affiliation: Unidad de Fibrosis Quística, Servicio de Neumología, Hospital Universitario de la Princesa, Madrid, España; Instituto de Investigación del Hospital de la Princesa, Madrid, España.
authors.forename: Rosa
authors.initials: R
authors.lastname: Girón
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D045247:Chryseobacterium / Q000302:isolation & purification / Q000472:pathogenicity*; D060085:Coinfection; D015897:Comorbidity; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology / Q000503:physiopathology; D004198:Disease Susceptibility; D004352:Drug Resistance, Microbial; D045826:Flavobacteriaceae Infections / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000821:virology*; D005541:Forced Expiratory Volume; D005838:Genotype; D006801:Humans; D015994:Incidence; D008168:Lung / Q000382:microbiology; D009894:Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology*; D010641:Phenotype; D011552:Pseudomonas Infections / Q000453:epidemiology; D013030:Spain / Q000453:epidemiology; D013203:Staphylococcal Infections / Q000453:epidemiology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
keywords: Chryseobacterium spp.; Cystic fibrosis; Fibrosis quística; Infección; Infection